Cargando…
Pharmacokinetic and technical comparison of Sandostatin(® )LAR(® )and other formulations of long-acting octreotide
BACKGROUND: Sandostatin(® )LAR(® )(Novartis Pharma AG) is a long-acting repeatable formulation of the somatostatin analogue octreotide, the safety and efficacy of which has been established through 15 years of clinical experience. Recently, other formulations of octreotide using polymer poly(lactic-...
Autores principales: | Petersen, Holger, Bizec, Jean-Claude, Schuetz, Helmut, Delporte, Marie-Laure |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3212992/ https://www.ncbi.nlm.nih.gov/pubmed/21906300 http://dx.doi.org/10.1186/1756-0500-4-344 |
Ejemplares similares
-
A Retrospective Interventional Cohort Study to Assess the Safety and Efficacy of Sandostatin LAR for Treatment of Recurrent and/or Refractory Meningiomas
por: Hrachova, Maya, et al.
Publicado: (2020) -
The effects of sandostatin (Octreotide, SMS 201-995) infusion on splanchnic and hepatic blood flow in an experimental model of hepatic metastases.
por: Hemingway, D. M., et al.
Publicado: (1992) -
Everolimus in combination with octreotide LAR in thymic atypical carcinoid
por: Sakane, Tadashi, et al.
Publicado: (2023) -
Sandostatin therapy in patients with chronic sarcoidosis
por: Timmermans, Wilhelmina M.C., et al.
Publicado: (2017) -
A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly
por: Mercado, Moises, et al.
Publicado: (2007)